Mayo Clinic launches Vancomycin clinical trial for Primary Sclerosing Cholangitis

Share this:

Jan 20, 2020 | Konstantinos N. Lazaridis, M.D. | @klazaridis

Mayo Clinic in Minnesota, Arizona and Florida is currently conducting a randomized placebo controlled clinical trial, examining the impact of oral vancomycin on markers of cholestasis among patients with PSC. The treatment period is approximately 18 months and requires about five clinic visits along with lab draws at home.

Please contact Mr. Mitch Clayton (study coordinator) at 507-284-2698 or clayton.mitchell@mayo.edu for additional details.

A link to the study on clinicaltrials.gov is provided below:

https://bit.ly/2RjImYP